Germany – Pharmaceutical products – Arzneimittel-Rabattverträge ab 01.02.2025 zu diversen Wirkstoffen im Rahmen eines Open-House-Verfahrens

Health · Germany government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

December 02, 2026
Response Due
Active
Status

Opportunity Overview

Germany – Pharmaceutical products – Drug rebate agreements from 01.02.2025 for various active ingredients within the framework of an open-house procedure

This Germany Pharmaceuticals opportunity is one most of your competitors will never see.

How to bid: GlobalGov tracks this tender; it does not accept bids. Submit your response through the issuing agency’s official notice.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start a free GlobalGov account

Solicitation Details

Issuing agencyHealth
CountryGermany
CategoryPharmaceuticals
PublishedDecember 12, 2024
Procurement stageActive solicitation
Response dueDecember 02, 2026
StatusOpen — accepting responses
Original languageGerman — members read it in their own language
Official sourceView original notice
Last verifiedOctober 11, 2026

Source: Tenders Electronic Daily (TED), © European Union. Notice content reused under Commission Decision 2011/833/EU; editorial content licensed CC BY 4.0. GlobalGov is not affiliated with the European Union.

Related Opportunities in Germany

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Tolterodin, ATC G04BD07
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Glatirameracetat, Fertigspritzen, ATC L03AX13
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130 a Abs. 8 SGB V mit dem Wirkstoff Doxylamin 6,96 mg / Pyridoxin 8,23 mg HVW (Cariban)
Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Flecainid (ATC-Code: C01BC04).
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Betahistin (ATC-Code nach WHO: N07CA01)
Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Fluorouracil (ATC: D11AF05)
Germany – Pharmaceutical products – Abschluss nicht exkl. Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum WS Ranibizumab (ATC-Code nach WHO: S01LA04) als Injektionslösung in einer Durchstechflasche
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Inclisiran, ATC C10AX16

See every Germany Pharmaceuticals opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free Germany Pharmaceuticals intelligence report in your inbox

A personalized report on Germany Pharmaceuticals opportunities, emailed in 5-10 minutes. One per month, no account needed.